Soft Palate Malignant Melanoma as an Adverse Effect of Fingolimod in Multiple Sclerosis: A Case Report and Literature Review

Author:

Paybast Sepideh,Mozhdehipanah Hossein,Safdarian Farshid

Publisher

Medknow

Subject

Neurology (clinical),Neurology

Reference11 articles.

1. FDA approves new oral drug to treat multiple sclerosis [Internet]. U.S. Food & Drug Administration. 2019. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-oral-drug-treat-multiple-sclerosis. [Last cited on 2019 Mar 26].

2. Fingolimod for multiple sclerosis and emerging indications: Appropriate patient selection, safety precautions, and special considerations;Ayzenberg;Ther Clin Risk Manag,2016

3. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): A double-blind, randomised, placebo-controlled, phase 3 trial;Calabresi;Lancet Neurol,2014

4. Melanoma occurring during treatment with fingolimod for multiple sclerosis: A case report;Conzett;Arch Dermatol,2011

5. Superficial spreading malignant melanoma in a patient on fingolimod therapy for multiple sclerosis;Haebich;Clin Exp Dermatol,2016

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Fingolimod;Reactions Weekly;2024-05-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3